LXRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LXRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Lexicon Pharmaceuticals's Capital Expenditure for the three months ended in Mar. 2025 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2025 was $-43.78 Mil.
GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.
The historical data trend for Lexicon Pharmaceuticals's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexicon Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Lexicon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Lexicon Pharmaceuticals's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Lexicon Pharmaceuticals's Capex-to-Operating-Cash-Flow falls into.
Lexicon Pharmaceuticals's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-1.031) | / | -178.78 | |
= | N/A |
Lexicon Pharmaceuticals's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2025 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (0) | / | -43.778 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexicon Pharmaceuticals (NAS:LXRX) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Philippe Amouyal | director | C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016 |
Lonnel Coats | director, officer: President and CEO | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Raymond Debbane | director, 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Thomas Garner | officer: SVP, Chief Commercial Officer | 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381 |
Jeffrey L Wade | officer: EVP, Gen. Counsel | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Wendy Mcdermott | officer: VP, Human Resources | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Diane E. Sullivan | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Artal International S.c.a. | director, 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
Invus Partners, Llc | director, 10 percent owner | 750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022 |
Ulys, Llc | director, 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
Kiernan Seth | officer: VP, Chief Commercial Officer | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Kenneth B. Kassler-taub | officer: SVP, Regulatory & QA | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Kristen Alexander | officer: VP, Finance and Accounting | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Craig B Granowitz | officer: SVP, Chief Medical Officer | 58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960 |
James F Tessmer | officer: VP, Finance & Acctg | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
From GuruFocus
By Marketwired • 11-06-2024
By GuruFocus News • 03-28-2025
By Marketwired • 12-20-2024
By GuruFocus News • 03-07-2025
By GuruFocus News • 12-18-2024
By GuruFocus News • 11-20-2024
By Marketwired • 11-26-2024
By Marketwired • 11-12-2024
By GuruFocus News • 11-13-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.